相关实验视频

Updated: Mar 1, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

BAP-1 抑制剂的设计和合成

Zheng Zhang¹, Xuchen Yang¹

¹Research Center for Exercise and Medicine Fusion, China Pharmaceutical University, Nanjing, Jiangsu, China.

Pakistan journal of pharmaceutical sciences

|February 28, 2026

概括

研究人员开发了新的BAP1抑制剂,以改善瘤治疗. 这些基于IBAP-II的新型化合物解决了溶解性问题,并增强了针对癌症治疗的抑制潜力.

科学领域:

药用化学医学化学
在瘤学瘤学.

背景情况:

恶性瘤需要先进的向治疗.
BRCA1结合蛋白1 (BAP1) 是一个在瘤发生过程中至关重要的二维基因酶.
BAP1 抑制剂 IBAP-II 是一个有前途的药物,但溶解性不佳.

研究的目的:

为了合成新的BAP1抑制剂,改进IBAP-II.
为了提高临床应用的可溶性和抑制功效.

主要方法:

通过迈克尔加法和苏子基-米亚乌拉反应合成了五种新型化合物.
IBAP-II作为衍生产品的主要结构.
1H NMR光谱学证实了合成化合物的结构.

主要成果:

成功合成了五种新的BAP1抑制剂衍生物.
收益率在27.86%至51.07%之间.
结构修改表明可能改善溶解性和结合亲和力.

结论:

为新型BAP1抑制剂建立了可行的合成途径.
这项研究为评估生物活动奠定了基础.
优化的BAP1抑制剂为小细胞肺癌等癌症提供了新的治疗前景.

关键词:

这是一种BAP1抑制剂.生物活动是生物活动.基因治疗是一种基因疗法.这就是IBAP-II.瘤是一个瘤.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones

Published on: July 25, 2019

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...